Vice President

Company Overview:

Beam Therapeutics is committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Position Overview:

Beam is looking for a highly energetic and dynamic leader as the VP of Product and Portfolio Strategy for Genetic Disease.  The VP will be responsible for shaping the life-cycle management and the path to commercialization for Beam’s liver in vivo portfolio (e.g., BEAM 302).  These therapies have the potential to be the first in vivo base editors designed to treat serious genetic disorders with a single infusion.  The VP will be responsible for shaping the product strategy for these medicines as well as build a global commercialization approach.

Responsibilities:

• Build the product strategy for BEAM 302 and 301 including life-cycle management and build pathway to commercialization.
• Create the roadmap to commercialization for rare disease therapy including commercial strategy, supply strategy, and building a global footprint.
• Shape the portfolio strategy for the liver portfolio including accelerating new targets.
• Lead the liver portfolio prioritization, forecasting, and opportunity assessment as a leader of the Program Team Strategy Cross-functional Sub-team.
• Collaborate closely with the Program lead, Program Manager, and key functions (e.g., clinical) to shape timelines, development operations, publications.
• Build the external communications approach for Liver Genetic Diseases (e.g., IR, science story).
• Monitor competitive intelligence and define differentiation strategy for in vivo editing.

Qualifications:

• BS/BA in a relevant academic field; MBA, MD, PhD, or other graduate degree strongly preferred with 20+ years of experience, 10+ years’ experience within the pharma/biotech/biopharma space in roles of progressively increasing responsibility.
• Extensive experience and track record with product strategy and commercial development with innovative medicines required.
• Genetic disease, gene therapy, and/or rare disease experience strongly desired.
• Proven track record in cross-functional leadership role or other cross-disciplinary background with successful team leadership experience required.
• Demonstrated ability to lead teams without direct reporting responsibility; exceptional interpersonal skills and collaborative nature with strong ability to influence, motivate, inspire, encourage and develop others.
• Driven by patient needs and comfortable operating in a highly scientific and technical environment while dealing with ambiguity.
• Strong collaboration, decision-making and conflict management skills with demonstrated proficiency.
• Excellent verbal and written communication skills including strong formal presentation skills and the ability to communicate complex scientific information in an understandable manner.
• Sophisticated understanding of the evolving scientific, clinical, regulatory, competitive, and economic trends impacting the industry, and able to adapt operational strategies accordingly.
• Experience in both large and small company environments a plus.